Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 4/20 | 0.57 |
| ▸ | NPC1 | O15118 | 3/20 | 0.57 |
| ▸ | MAPT | P10636 | 1/20 | 0.57 |
| ▸ | MET | P08581 | 5/20 | 0.56 |
| ▸ | LTA4H | P09960 | 1/20 | 0.50 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | JAK2 | O60674 | 2/20 | 0.45 |
| ▸ | MAP4K3 | Q8IVH8 | 1/20 | 0.45 |
| ▸ | SYK | P43405 | 1/20 | 0.38 |
| ▸ | SGMS2 | Q8NHU3 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL488397 | 0.92 | LTA4H (0.53) | RAB9ANPC1MAPTMETLTA4H | |
| SCHEMBL14812299 | 0.86 | MET (0.54) | RAB9ANPC1MAPTMETLTA4H | |
| SCHEMBL488813 | 0.84 | RAB9A (0.55) | RAB9ANPC1MAPTMETLTA4H | |
| SCHEMBL488951 | 0.82 | NPC1 (0.61) | RAB9ANPC1MAPTMETLTA4H | |
| SCHEMBL15779203 | 0.81 | MET (0.50) | RAB9ANPC1MAPTMETLTA4H | |
| SCHEMBL9123661 | 0.80 | LTA4H (0.55) | RAB9ANPC1MAPTMETLTA4H | |
| SCHEMBL488298 | 0.79 | LTA4H (0.58) | RAB9ANPC1MAPTMETLTA4H | |
| SCHEMBL3019351 | 0.78 | LTA4H (0.54) | RAB9ANPC1MAPTMETLTA4H | |
| SCHEMBL488754 | 0.78 | NPC1 (0.61) | RAB9ANPC1MAPTHTTKDM4E | |
| SCHEMBL6079136 | 0.78 | NPC1 (0.77) | RAB9ANPC1MAPTMETLTA4H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160206608-A1 | CRIZOTINIB FOR USE IN THE TREATMENT OF CANCER | PFIZER INC. (US) | 2016-07-21 | — | — | US | disclosed |
| US-20160015702-A1 | AMINOHETEROARYL COMPOUNDS AS MTH1 INHIBITORS | CEMM - FORSCHUNGSZENTRUM FÜR MOLEKULARE MEDIZIN GMBH (AT) | 2016-01-21 | — | — | US | disclosed |
| US-20140288086-A1 | ENANTIOMERICALLY PURE AMINOHETEROARYL COMPOUNDS AS PROTEIN KINASE INHIBITORS | PFIZER INC. (US) | 2014-09-25 | — | — | US | disclosed |
| EP-2764866-A1 | Inhibitors of nedd8-activating enzyme | IP Gesellschaft für Management mbH (DE) | 2014-08-13 | — | — | EP | disclosed |
| US-8785632-B2 | Enantiomerically pure aminoheteroaryl compounds as protein kinase inhibitors | AGOURON PHARMACEUTICALS, INC. (US) | 2014-07-22 | — | — | US | disclosed |
| EP-2739284-A1 | CRIZOTINIB FOR USE IN THE TREATMENT OF CANCER | Pfizer Inc (US) | 2014-06-11 | — | — | EP | disclosed |
| EP-1603570-B9 | AMINOHETEROARYL COMPOUNDS AS PROTEIN KINASE INHIBITORS | SUGEN INC (US) | 2013-10-23 | — | — | EP | disclosed |
| EP-1786785-B9 | ENANTIOMERICALLY PURE AMINOHETEROARYL COMPOUNDS AS PROTEIN KINASE INHIBITORS | PFIZER (US) | 2013-05-22 | — | — | EP | disclosed |
| EP-1963302-B1 | POLYMORPHS OF A C-MET/HGFR INHIBITOR | PFIZER PROD INC (US) | 2013-02-27 | — | — | EP | disclosed |
| WO-2013017989-A1 | CRIZOTINIB FOR USE IN THE TREATMENT OF CANCER | PFIZER INC. (US) | 2013-02-07 | — | — | WO | disclosed |
| US-20070072874-A1 | Aminoheteroaryl compounds as protein kinase inhibitors | SUGEN, INC. | 2007-03-29 | — | — | US | disclosed |
| US-20060178374-A1 | Aminoheteroaryl compounds as protein kinase inhibitors | AGOURON PHARMACEUTICALS, INC. | 2006-08-10 | — | — | US | disclosed |
| US-20060128724-A1 | Pyrazole-substituted aminoheteroaryl compounds as protein kinase inhibitors | AGOURON PHARMACEUTICALS, INC. | 2006-06-15 | — | — | US | disclosed |
| US-20060046991-A1 | Crizotinib, a c-Met protein kinase inhibitor anticancer agent; 3-[(R)-1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine is crizotinib | AGOURON PHARMACEUTICALS, INC. | 2006-03-02 | — | — | US | disclosed |
| WO-2006021884-A2 | ENANTIOMERICALLY PURE AMINOHETEROARYL COMPOUNDS AS PROTEIN KINASE INHIBITORS | PFIZER INC. (US) | 2006-03-02 | — | — | WO | disclosed |
| WO-2006021881-A2 | PYRAZOLE-SUBSTITUTED AMINOHETEROARYL COMPOUNDS AS PROTEIN KINASE INHIBITORS | PFIZER INC. (US) | 2006-03-02 | — | — | WO | disclosed |
| WO-2006021886-A1 | AMINOHETEROARYL COMPOUNDS AS PROTEIN TYROSINE KINASE INHIBITORS | PFIZER INC. (US) | 2006-03-02 | — | — | WO | disclosed |
| EP-1603570-A2 | AMINOHETEROARYL COMPOUNDS AS PROTEIN KINASE INHIBITORS | Sugen, Inc. (US) | 2005-12-14 | — | — | EP | disclosed |
| US-20050009840-A1 | 2-amino- pyridines and pyrazines additionally substituted witn one or more carbocyclic or heterocyclic groups, e.g., 4-[6-amino-5-(2,6-dichloro-benzyloxy)-pyridin-3-yl]-phenol, for treating many kinds of cancer | SUGEN, INC. | 2005-01-13 | — | — | US | disclosed |
| WO-2004076412-A2 | AMINOHETEROARYL COMPOUNDS AS PROTEIN KINASE INHIBITORS | SUGEN, INC. (US) | 2004-09-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160206608-A1 | CRIZOTINIB FOR USE IN THE TREATMENT OF CANCER | ROS1, ALK, ABL1 | RAB9A 1222/4885NPC1 1614/4885MAPT 2976/4885 |
| US-20060128724-A1 | Pyrazole-substituted aminoheteroaryl compounds as protein kinase inhibitors | MET, MAP3K15, MAP3K19 | RAB9A 2293/4885NPC1 3013/4885MAPT 3054/4885 |
| US-20060046991-A1 | Crizotinib, a c-Met protein kinase inhibitor anticancer agent; 3-[(R)-1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine is crizotinib | ALK, MET, ERBB2 | RAB9A 2360/4885NPC1 1623/4885MAPT 2644/4885 |
| US-20160015702-A1 | AMINOHETEROARYL COMPOUNDS AS MTH1 INHIBITORS | MTHFD1, NUDT15, NUDT1 | RAB9A 3406/4885NPC1 299/4885MAPT 1118/4885 |
| US-20060178374-A1 | Aminoheteroaryl compounds as protein kinase inhibitors | MET, MAP3K15, CDC42BPA | RAB9A 2192/4885NPC1 3401/4885MAPT 2603/4885 |
| US-20050009840-A1 | 2-amino- pyridines and pyrazines additionally substituted witn one or more carbocyclic or heterocyclic groups, e.g., 4-[6-amino-5-(2,6-dichloro-benzyloxy)-pyridin-3-yl]-phenol, for treating many kinds of cancer | MET, ERBB2, CDK4 | RAB9A 2731/4885NPC1 4515/4885MAPT 2514/4885 |
| US-20070072874-A1 | Aminoheteroaryl compounds as protein kinase inhibitors | MET, MAP4K1, MAP4K2 | RAB9A 2752/4885NPC1 3437/4885MAPT 2035/4885 |
| US-20140288086-A1 | ENANTIOMERICALLY PURE AMINOHETEROARYL COMPOUNDS AS PROTEIN KINASE INHIBITORS | MET, MAP3K15, MAP3K1 | RAB9A 2368/4885NPC1 2029/4885MAPT 2839/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.